Egfr Mutation Positive Unresectable Or Recurrent Non Small Cell Lung Cancer — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for egfr mutation positive unresectable or recurrent non small cell lung cancer. 3 active patents protecting 1 drugs from 1+ originators. First major cliff: 2032. Daily refresh.

Originators in Egfr Mutation Positive Unresectable Or Recurrent Non Small Cell Lung Cancer

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating egfr mutation positive unresectable or recurrent non small cell lung cancer. Each bar = one year. Y-axis scaled to peak year (3 patents).

Approved drugs ranked by patent estate

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Related

• Egfr Mutation Positive Unresectable Or Recurrent Non Small Cell Lung Cancer — full disease profile
• AI Patent Landscape Report — type "egfr mutation positive unresectable or recurrent non small cell lung cancer" for an AI exec memo
• Company Patent Rankings
• Biosimilar Opportunity Scanner